ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis

作者：Rios Danyelle R A; Carvalho Maria G; Figueiredo Roberta C; Ferreira Claudia N; Rodrigues Valerio L; Souza Regina A; Silva Ana C Simoes e; Fernandes Ana Paula; Gomes Karina B; Dusse Luci M S^*

来源：Journal of Thrombosis and Thrombolysis, 2012, 34(1): 73-78.

DOI：10.1007/s11239-012-0682-1

• Hemodialysis
• ADAMTS13
• VWF
• Vascular access thrombosis

Hemodialysis (HD) is associated with increasing thrombotic trend. Vascular access thrombosis (VAT) increases morbidity in HD patients. The aim of this study was to evaluate ADAMTS13 and VWF plasma levels from patients undergoing HD as putative biomarkers of the hypercoagulability state, as well the association between these markers and VAT occurrence. This study included 195 patients on HD for more than 6 months. HD patients were allocated into two groups according to the occurrence or not of previous episode of VAT; HD with VAT (N = 46) and HD without VAT (N = 149). ADAMTS13 and VWF were performed by ELISA. There was no significant difference between HD patients with and without VAT for ADAMTS13 and VWF levels. However, VWF levels were higher (P %26lt; 0.001) and ADAMTS13 were lower (P %26lt; 0.001) in HD patients, comparing to the control group composed by healthy subjects without kidney disease, age and sex-matched (N = 80). Taken together our data suggest a potential role of the kidneys function compromised on ADAMTS13 synthesis or metabolism, regardless other known sources of ADAMTS13. The imbalance between ADAMTS13 and VWF levels does not explain the development of VAT in HD patients by itself, although it should contribute for the hypercoagulability state. Therefore, additional studies to identify other risk factors are warranted and essential for better management of HD patients.

• 出版日期2012-7